BRD7 deficiency leads to the development of obesity and hyperglycemia

Area of Science:

• Metabolic diseases
• Molecular mechanisms of obesity
• Liver function

Background:

• Obesity is a global epidemic with incompletely understood molecular drivers.
• Bromodomain-containing protein 7 (BRD7) expression is reduced in the livers of obese mice.
• The direct role of hepatic BRD7 in obesity and glucose homeostasis is unclear.

Purpose of the Study:

• To investigate the association between hepatic BRD7 levels and obesity development.
• To determine the impact of reduced BRD7 on glucose metabolism.
• To evaluate the protective effects of upregulating hepatic BRD7 against diet-induced metabolic dysfunction.

Main Methods:

• Utilized heterozygous BRD7 knockout mouse models.
• Employed liver-specific BRD7 knockout mouse models.
• Assessed weight gain, glucose tolerance, and insulin resistance in response to dietary challenges.

Main Results:

• Reduced BRD7 levels in the liver led to increased weight gain.
• Decreased hepatic BRD7 had minimal impact on glucose metabolism.
• Early upregulation of liver BRD7 conferred protection against high-fat diet-induced weight gain, glucose intolerance, and insulin resistance.

Conclusions:

• Hepatic BRD7 plays a significant role in regulating body weight and preventing diet-induced obesity.
• BRD7 modulation in the liver offers a potential therapeutic target for obesity and related metabolic disorders.
• Early intervention with BRD7 upregulation may be crucial for metabolic health.